Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tg Therapeutics (TGTX) Income from Continuing Operations (2016 - 2025)

Tg Therapeutics has reported Income from Continuing Operations over the past 10 years, most recently at 84657000.0 for Q4 2025.

  • Quarterly results put Income from Continuing Operations at 84657000.0 for Q4 2025, down 449.72% from a year ago — trailing twelve months through Dec 2025 was 339485000.0 (up 1300.11% YoY), and the annual figure for FY2025 was 339440000.0, up 1299.23%.
  • Income from Continuing Operations for Q4 2025 was 84657000.0 at Tg Therapeutics, down from 390895000.0 in the prior quarter.
  • Over the last five years, Income from Continuing Operations for TGTX hit a ceiling of 390895000.0 in Q3 2025 and a floor of 94026000.0 in Q4 2021.
  • Median Income from Continuing Operations over the past 5 years was 37921500.0 (2022), compared with a mean of 10125450.0.
  • Peak annual rise in Income from Continuing Operations hit 10005.87% in 2025, while the deepest fall reached 449.72% in 2025.
  • Tg Therapeutics' Income from Continuing Operations stood at 94026000.0 in 2021, then rose by 14.49% to 80401000.0 in 2022, then skyrocketed by 82.07% to 14416000.0 in 2023, then skyrocketed by 267.92% to 24207000.0 in 2024, then tumbled by 449.72% to 84657000.0 in 2025.
  • The last three reported values for Income from Continuing Operations were 84657000.0 (Q4 2025), 390895000.0 (Q3 2025), and 28187000.0 (Q2 2025) per Business Quant data.